SCA
MDGL icon

Snowden Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Snowden Capital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
1,952
-431
-18% -$221K 0.02% 560
2026
Q1 		$1.25M Buy
2,383
+158
+7% +$75.5K 0.03% 465
2025
Q4 		$1.3M Sell
2,225
-285
-11% -$146K 0.03% 443
2025
Q3 		$1.15M Buy
2,510
+392
+19% +$146K 0.03% 478
2025
Q2 		$641K Sell
2,118
-14
-0.7% -$4.17K 0.02% 665
2025
Q1 		$706K Buy
2,132
+227
+12% +$74.6K 0.02% 615
2024
Q4 		$588K Buy
1,905
+366
+24% +$103K 0.02% 703
2024
Q3 		$327K Buy
1,539
+77
+5% +$19.7K 0.01% 954
2024
Q2 		$410K Buy
+1,462
New +$348K 0.01% 845

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Snowden Capital Advisors's MDGL Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 18% in Q2 2026, selling an estimated $221K and leaving 1,952 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #560.

Snowden Capital Advisors first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.3M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Snowden Capital Advisors held 1,952 shares of Madrigal Pharmaceuticals worth $1.05M as of Q2 2026.
  • Snowden Capital Advisors sold 431 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $221K.
  • Madrigal Pharmaceuticals made up 0.02% of Snowden Capital Advisors's portfolio in Q2 2026, its #560 holding.
  • Snowden Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Snowden Capital Advisors's Madrigal Pharmaceuticals position peaked at $1.3M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.